West Virginia House Bill HB2315

West Virginia 2025 Regular Session

• Introduced: 2/12/25
• Refer: 2/12/25

Caption

Relating to authorizing the Board of Pharmacy to promulgate a legislative rule relating to the application of waiver of initial licensing fees for certain individuals

Summary

HB2315 is a rule-authorization bill that gives legislative approval to a West Virginia Board of Pharmacy rule concerning how certain individuals may receive a waiver of initial licensing fees. The bill does not itself create a new licensing program or change the underlying pharmacy licensing statutes; instead, it authorizes the Board of Pharmacy to proceed with a specific legislative rule already filed in the State Register. The practical effect is to allow the Board of Pharmacy to implement administrative rules at 15 CSR 18 governing eligibility and application procedures for initial fee waivers. The bill is limited in scope and is focused on the regulatory process for pharmacy-related licensing fees, likely affecting applicants who qualify for fee relief under the board’s rule.

Impact

HB2315 amends §64-9-1 of the West Virginia Code to add the Board of Pharmacy’s rule on waiver of initial licensing fees for certain individuals to the list of authorized legislative rules. Its impact is procedural: it validates the board’s authority to enforce the rule and thereby affects pharmacy license applicants who may seek an initial fee waiver, while leaving the substantive details of eligibility and administration to the board’s rulemaking process.

Sentiment

The available record suggests little to no controversy around HB2315. There are no committee transcripts, recorded votes, or opposing statements in the provided materials, and the bill appears to be a routine authorization of an agency rule. The overall sentiment is best characterized as neutral and administrative, with the measure presented as a standard legislative approval of a Board of Pharmacy rule.

Contention

No specific points of contention are evident in the provided materials. Because the bill simply authorizes a legislative rule rather than debating the merits of the fee waiver policy itself, any disagreement would likely center on the scope of the Board of Pharmacy’s authority, who qualifies for the waiver, or the fiscal and administrative effects of reducing initial licensing fees. However, none of those issues are documented in the supplied transcripts or vote history.